BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26072418)

  • 1. Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors.
    Papa S; van Schalkwyk M; Maher J
    Methods Mol Biol; 2015; 1317():365-82. PubMed ID: 26072418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
    Klampatsa A; Achkova DY; Davies DM; Parente-Pereira AC; Woodman N; Rosekilly J; Osborne G; Thayaparan T; Bille A; Sheaf M; Spicer JF; King J; Maher J
    Cancer Lett; 2017 May; 393():52-59. PubMed ID: 28223167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study.
    Papa S; Adami A; Metoudi M; Beatson R; George MS; Achkova D; Williams E; Arif S; Reid F; Elstad M; Beckley-Hoelscher N; Douri A; Delord M; Lyne M; Shivapatham D; Fisher C; Hope A; Gooljar S; Mitra A; Gomm L; Morton C; Henley-Smith R; Thavaraj S; Santambrogio A; Andoniadou C; Allen S; Gibson V; Cook GJR; Parente-Pereira AC; Davies DM; Farzaneh F; Schurich A; Guerrero-Urbano T; Jeannon JP; Spicer J; Maher J
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37321663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Chemoimmunotherapy of Epithelial Ovarian Cancer Using ErbB-Retargeted T Cells Combined with Carboplatin.
    Parente-Pereira AC; Whilding LM; Brewig N; van der Stegen SJ; Davies DM; Wilkie S; van Schalkwyk MC; Ghaem-Maghami S; Maher J
    J Immunol; 2013 Sep; 191(5):2437-45. PubMed ID: 23898037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer.
    van Schalkwyk MC; Papa SE; Jeannon JP; Guerrero Urbano T; Spicer JF; Maher J
    Hum Gene Ther Clin Dev; 2013 Sep; 24(3):134-42. PubMed ID: 24099518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?
    van der Stegen SJ; Davies DM; Wilkie S; Foster J; Sosabowski JK; Burnet J; Whilding LM; Petrovic RM; Ghaem-Maghami S; Mather S; Jeannon JP; Parente-Pereira AC; Maher J
    J Immunol; 2013 Nov; 191(9):4589-98. PubMed ID: 24062490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ErbB-targeted CAR T-cell immunotherapy of cancer.
    Whilding LM; Maher J
    Immunotherapy; 2015; 7(3):229-41. PubMed ID: 25804476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
    Zeltsman M; Dozier J; McGee E; Ngai D; Adusumilli PS
    Transl Res; 2017 Sep; 187():1-10. PubMed ID: 28502785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.
    Morello A; Sadelain M; Adusumilli PS
    Cancer Discov; 2016 Feb; 6(2):133-46. PubMed ID: 26503962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
    Beatty GL; Haas AR; Maus MV; Torigian DA; Soulen MC; Plesa G; Chew A; Zhao Y; Levine BL; Albelda SM; Kalos M; June CH
    Cancer Immunol Res; 2014 Feb; 2(2):112-20. PubMed ID: 24579088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.
    Whilding LM; Parente-Pereira AC; Zabinski T; Davies DM; Petrovic RMG; Kao YV; Saxena SA; Romain A; Costa-Guerra JA; Violette S; Itamochi H; Ghaem-Maghami S; Vallath S; Marshall JF; Maher J
    Mol Ther; 2017 Jan; 25(1):259-273. PubMed ID: 28129120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 13. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective Targeting of TAG72
    Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
    Front Immunol; 2018; 9():2268. PubMed ID: 30510550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4.
    Wilkie S; Burbridge SE; Chiapero-Stanke L; Pereira AC; Cleary S; van der Stegen SJ; Spicer JF; Davies DM; Maher J
    J Biol Chem; 2010 Aug; 285(33):25538-44. PubMed ID: 20562098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
    Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
    J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review.
    Zhang J; Wang L
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819831068. PubMed ID: 30798772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
    Petrausch U; Schuberth PC; Hagedorn C; Soltermann A; Tomaszek S; Stahel R; Weder W; Renner C
    BMC Cancer; 2012 Dec; 12():615. PubMed ID: 23259649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.